June 2022 // Communication

Read about our success story in an article published by NCCR Transcure

In a last newsletter edition from NCCR Transcure, we can look behind the scenes of our technology transfer success story. Prof. Jürg Gertsch together with our CEO Andrea Chicca, illustrate the path that led to the conception and launch of Synendos Therapeutics, a spin-off of NCCR TransCure and University of Bern. Read the full article here:

https://www.nccr-transcure.ch/communication/newsletter/newsletter-no-17/synendos-therapeutics

Recent Posts

See All

July 2023 // Communication

Synendos Therapeutics AG announces that co-founder and Scientific Advisor Board member, Professor Jürg Gertsch, presented groundbreaking new findings on an endocannabinoid transporter at the 10th Gord

March 2023 // Communication Synendos featured in Scrip article

The most recent ‘Scrip Asks’ instalments from the ‘What Does 2023 Hold For Biopharma’ series focuses on therapeutic area advances and includes an overview on the potential in CNS. Our CEO/CSO Andrea C

September 2022 // Company & Communication

Synendos Therapeutics is ranked TOP 100 Swiss Startups 2022 We are honored to be listed for the second year in a row as one of the TOP 100 Swiss Startups 2022. A big thank you to our team, partners, c

FOUNDING TEAM

FOUNDING TEAM

FOUNDING TEAM

FOUNDING TEAM

PD Dr. Andrea Chicca

Prof. Dr. Jürg Gertsch

June 2022 // Communication

Recent Posts